Back to top

Image: Bigstock

Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session

Read MoreHide Full Article

Pieris Pharmaceuticals, Inc. (PIRS - Free Report) was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.64 to $6.37 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Pieris Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Biomedical and Genetics industry may consider Protagonist Therapeutics, Inc. (PTGX - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is PIRS going up? Or down? Predict to see what others think:Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>
 


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Pieris Pharmaceuticals, Inc. (PIRS) - free report >>

Protagonist Therapeutics, Inc. (PTGX) - free report >>

Published in